Table 2.
Antimicrobial Resistance of T6SS‐positive and T6SS‐negative K. pneumoniae Bloodstream Isolates
| Antimicrobial Susceptibility, n (%) | All (n = 119) | T6SS‐Positive (n = 20) | T6SS‐Negative (n = 99) | p |
|---|---|---|---|---|
| Aztreonam | 65 (54.6) | 6 (30.0) | 59 (59.6) | 0.01 |
| Gentamicin | 58 (48.7) | 5 (25.0) | 53 (53.5) | 0.02 |
| Tobramycin | 45 (37.8) | 3 (15.0) | 42 (42.4) | 0.02 |
| Trimethoprim sulfamethoxazole | 51 (42.8) | 5 (25.0) | 46 (46.5) | 0.07 |
| Amikacin | 38 (31.9) | 3 (15.0) | 35 (35.4) | 0.07 |
| Cefepime | 56 (47.0) | 6 (30.0) | 50 (50.5) | 0.09 |
| Ceftriaxone | 75 (63.0) | 8 (40.0) | 67 (67.7) | 0.01 |
| Cefotaxime | 76 (63.8) | 8 (40.0) | 68 (68.7) | 0.015 |
| Ceftazidime | 62 (52.1) | 6 (30.0) | 56 (56.6) | 0.03 |
| Cefoperazone‐sulbactam | 57 (47.8) | 4 (20.0) | 53 (53.5) | 0.006 |
| Ciprofloxacin | 68 (57.1) | 4 (20.0) | 64 (64.6) | <0.001 |
| Levofloxacin | 58 (48.7) | 3 (15.0) | 55 (55.6) | 0.001 |
| Imipenem | 50 (42.0) | 4 (20.0) | 46 (46.5) | 0.029 |
| Meropenem | 50 (42.0) | 4 (20.0) | 46 (46.5) | 0.029 |
| Ampicillin‐sulbactam | 79 (66.3) | 8 (40.0) | 71 (71.7) | 0.006 |
| Piperacillin‐tazobactam | 54 (45.3) | 4 (20.0) | 50 (50.5) | 0.01 |
| Minocycline | 11 (9.2) | 0 | 11 (11.1) | 0.118 |
| Piperacillin | 85 (71.4) | 9 (45.0) | 76 (76.8) | 0.004 |
| Tigecycline | 1 (0.8) | 0 | 1 (1.0) | 0.652 |
| Ceftazidime - avibatan | 11 (9.2) | 1 (5.0) | 10 (10.1) | 0.473 |
| CRKP | 49 (41.2) | 4 (20.0) | 45 (45.4) | 0.03 |
| ESBL | 24 (20.2) | 4 (20.0) | 20 (20.2) | 0.98 |
Abbreviations: CRKP, carbapenem-resistant KP; ESBL, extended-spectrum β-lactamase.